Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS

Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
AIDS (London, England) (Impact Factor: 5.55). 04/2009; 23(6):701-6. DOI: 10.1097/QAD.0b013e32832605fe
Source: PubMed


To assess impact of serial lumbar punctures on association between cerebrospinal fluid (CSF) opening pressure and prognosis in HIV-associated cryptococcal meningitis; to explore time course and relationship of opening pressure with neurological findings, CSF fungal burden, immune response, and CD4 cell count.
Evaluation of 163 HIV-positive ART-naive patients enrolled in three trials of amphotericin B-based therapy for cryptococcal meningitis in Thailand and South Africa.
Study protocols required four lumbar punctures with measurements of opening pressure over the first 2 weeks of treatment and additional lumbar punctures if opening pressure raised. Fungal burden and clearance, CSF immune parameters, CD4 cell count, neurological symptoms and signs, and outcome at 2 and 10 weeks were compared between groups categorized by opening pressure at cryptococcal meningitis diagnosis.
Patients with higher baseline fungal burden had higher baseline opening pressure. High fungal burden appeared necessary but not sufficient for development of high pressure. Baseline opening pressure was not associated with CD4 cell count, CSF pro-inflammatory cytokines, or altered mental status. Day 14 opening pressure was associated with day 14 fungal burden. Overall mortality was 12% (20/162) at 2 weeks and 26% (42/160) at 10 weeks, with no significant differences between opening pressure groups.
Studies are needed to define factors, in addition to fungal burden, associated with raised opening pressure. Aggressive management of raised opening pressure through repeated CSF drainage appeared to prevent any adverse impact of raised opening pressure on outcome in patients with cryptococcal meningitis. The results support increasing access to manometers in resource-poor settings and routine management of opening pressure in patients with cryptococcal meningitis.

Download full-text


Available from: Angela Loyse,
  • Source
    • "Raised intracranial pressure is an extremely common complication of cryptococcal meningitis and is associated with sometimes profound and irreversible visual and hearing loss (Graybill et al., 2000). Whilst host factors may play a role, there is evidence for pathophysiology due to fungal factors, with a combination of a high fungal burden and infection with highly encapsulated strains obstructing CSF outflow and causing a communicating hydrocephalus (Bicanic et al., 2009; Robertson et al., 2014). Raised intracranial pressure will resolve with time, so to avert irreversible morbidity, management is by frequent, sometimes daily, large volume (up to 30–40 ml) therapeutic CSF taps or temporary diversion using lumbar or ventricular drains (Perfect et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epidemiology has been focused on three major outbreaks of disease that reflects both changing environmental exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have been bolstered by identification of the yeast’s dynamic genomic structures and functions. It is during these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this infection with a new point-of-care, simple, cheap test which utilizes a lateral flow assay for antigen detection. With methods for effective identification of Cryptococcus in the host, the principles for management of this deadly infection include both use of old drugs and new insights into treatment strategies to improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to summarize our present knowledge base for this deadly fungal central nervous system infection with a particular emphasis on its diagnosis and management.
    Fungal Genetics and Biology 10/2014; 301. DOI:10.1016/j.fgb.2014.10.003 · 2.59 Impact Factor
  • Source
    • "Widening access to optimal antifungal therapy requires urgent action if this high associated mortality is to be reduced to the lower levels reported from developed country settings (10 week mortality 10%–26%).60,68 Improving access to essential antifungals must be achieved alongside efforts to treat patients earlier through improved diagnostics85 and effective management of CM complications such as raised intracranial pressure.86 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden is greatest, is inadequate at present. While research into identifying effective and well-tolerated antifungal combinations that do not contain flucytosine continues, an ever-increasing body of evidence from in vitro, in vivo and clinical studies points to the benefits of flucytosine in the treatment of CM in both intravenous combinations with amphotericin B and oral combinations with high-dose fluconazole. This article provides an up-to-date review of this evidence, and the current issues and challenges regarding increasing access to this key component of combination antifungal therapy for cryptococcosis.
    Journal of Antimicrobial Chemotherapy 06/2013; 68(11). DOI:10.1093/jac/dkt221 · 5.31 Impact Factor
  • Source
    • "Also, our hospital does not have the equipment necessary for intensive intracranial pressure management, which has been associated with decreased mortality in cryptococcal meningitis and is recommended by the Infectious Diseases Society of America [12,22]. One possible benefit of the early, targeted screening of inpatients with the serum CRAG is that early, aggressive, empiric ICP management could be initiated on CRAG-positive patients according to the protocol recommended by Bicanic et al [23]. Finally, patients in our setting often present for medical care late in the course of their illness [24,25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cryptococcal meningitis is a leading cause of death among HIV-infected individuals in sub-Saharan Africa. Recent developments include the availability of intravenous fluconazole, cryptococcal antigen assays and new data to support fluconazole pre-emptive treatment. In this study, we describe the impact of screening HIV-positive adult inpatients with serum cryptococcal antigen (CRAG) at a Tanzanian referral hospital. All adults admitted to the medical ward of Bugando Medical Centre are counseled and tested for HIV. In this prospective cohort study, we consecutively enrolled HIV-positive patients admitted between September 2009 and January 2010. All patients were interviewed, examined and screened with serum CRAG. Patients with positive serum CRAG or signs of meningitis underwent lumbar puncture. Patients were managed according to standard World Health Organization treatment guidelines. Discharge diagnoses and in-hospital mortality were recorded. Of 333 HIV-infected adults enrolled in our study, 15 (4.4%) had confirmed cryptococcal meningitis and 10 of these 15 (66%) died. All patients with cryptococcal meningitis had at least two of four classic symptoms and signs of meningitis: fever, headache, neck stiffness and altered mental status. Cryptococcal meningitis accounted for a quarter of all in-hospital deaths. Despite screening of all HIV-positive adult inpatients with the serum CRAG at the time of admission and prompt treatment with high-dose intravenous fluconazole in those with confirmed cryptococcal meningitis, the in-hospital mortality rate remained unacceptably high. Improved strategies for earlier diagnosis and treatment of HIV, implementation of fluconazole pre-emptive treatment for high-risk patients and acquisition of better resources for treatment of cryptococcal meningitis are needed.
    Journal of the International AIDS Society 10/2011; 14(1):48. DOI:10.1186/1758-2652-14-48 · 5.09 Impact Factor
Show more